XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

NCCTG clinical trial N9831

Breast Channel
subscribe to Breast newsletter

Latest Research : Cancer : Breast

   DISCUSS   |   EMAIL   |   PRINT
Safe side effect profile for HER-2 positive breast cancer patients using trastuzumab
Jun 6, 2006, 01:29, Reviewed by: Dr. Priya Saxena

"We hoped also to show that trastuzumab did not add complications to radiation treatment, and the current study has certainly proven that, providing good news for many women."

 
Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.

This study resulted from NCCTG clinical trial N9831, from which breakthrough treatment findings were presented at ASCO 2005. "The original N9831 study showed that trastuzumab reduced the recurrence of HER-2 positive breast cancer about 50 percent," says Dr. Halyard, a radiation oncologist at Mayo Clinic Arizona and lead author of today's study. "We hoped also to show that trastuzumab did not add complications to radiation treatment, and the current study has certainly proven that, providing good news for many women."

About 25 percent to 30 percent of breast cancers produce an overabundance of a growth-promoting protein called human epidermal growth factor receptor (HER-2). These tumors tend to grow faster and are generally more likely to recur than tumors that do not overproduce HER-2. Trastuzumab is the first identified monoclonal antibody designed specifically to attack this overexpressed protein, and is used as a follow-on treatment to chemotherapy. A monoclonal antibody is a laboratory-engineered protein that helps the body's immune system fight foreign invaders such as cancer.

Dr. Halyard's study looked at the side effects related to adding trastuzumab to radiation therapy. In the 1,460 patients who received radiation in the original N9831 group, there was no significant difference in the incidence of skin reactions, pneumonitis, dyspnea, cough, esophageal dysphagia or neutropenia between those who received trastuzumab (908), and those who did not (552). Additionally, the researchers report that within the group of 1,286 patients who received trastuzumab, those who had radiation (908) were no more likely to have cardiac complications than those who did not (378).
 

- Mayo Clinic's Michele Halyard, M.D., presented these findings on June 5, at the 2006 American Society of Clinical Oncology (ASCO) annual meeting in Atlanta.
 

cancercenter.mayo.edu/mayo/research/womens_cancer

 
Subscribe to Breast Newsletter
E-mail Address:

 

The NCCTG trastuzumab trial was led by Mayo Clinic Jacksonville's Edith Perez, M.D., with Dr. Halyard as a co-investigator. It was a cooperative effort with the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and the Cancer and Leukemia Group B (CALGB). Study co-investigators included Mayo Clinic Rochester's Thomas Pisansky, M.D.; and Amylou Dueck, Ph.D.; along with Lori Pierce, M.D., University of Michigan; Lawrence Solin, M.D., University of Pennsylvania; and Lawrence Marks, M.D., Duke University.

The study presented is one of several studies resulting from information gained in NCCTG clinical trial N9831. NCCTG is a national clinical research group sponsored by the National Cancer Institute. Research is based at Mayo Clinic. NCCTG consists of a network of cancer specialists at community clinics, hospitals and medical centers in the United States, Canada and Mexico. The group is dedicated to bringing clinical trials with promising new cancer therapies to communities where patients live.

Trastuzumab, trade name Herceptin®, is manufactured by Genentech, which provided some support for this study, along with the National Institutes of Health and the Breast Cancer Research Foundation.

For more information on breast cancer research at Mayo Clinic, visit http://cancercenter.mayo.edu/mayo/research/womens_cancer. To find out more about NCCTG and available clinical trials, visit http://ncctg.


Related Breast News

Breast cancer chemotherapy may deterioration in cognitive function
Elderly Breast Cancer Patients May Be Under-Diagnosed And Under-Treated
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Ethnic variations in hormone levels may cause differences in breast cancer risk
Researchers set benchmarks for screening mammography
Raloxifene Reduces Breast Cancer Risk in Postmenopausal Women at All Risk Levels
Physical activity improves survival in breast cancer patients
Pedigree assessment tool correctly identifies women with higher risk of breast cancer
MRI more accurately determines cancer spread into breast ducts
Core needle biopsy gives an accurate picture of gene expression


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us